Corbus Pharmaceuticals Holdings (CRBP) Net Cash Flow (2013 - 2025)

Corbus Pharmaceuticals Holdings' Net Cash Flow history runs 13 years deep, the most recent figure standing at $6.9 million for Q3 2025.

• On a quarterly basis, Net Cash Flow rose 262.77% year-over-year to $6.9 million in Q3 2025; TTM through Dec 2025 was $9.8 million, a 181.66% increase from a year earlier, with the FY2024 full-year figure at $3.5 million, up 205.95% from the prior year.
• Net Cash Flow grew to $6.9 million in Q3 2025 per CRBP's latest filing, from $1.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $32.0 million in Q1 2022 and bottomed at -$31.3 million in Q2 2022.
• The 5-year median for Net Cash Flow is $1.0 million (2023), against an average of -$3.1 million.
• Across the five-year window, Net Cash Flow slumped 1383.47% in 2022 and soared 835.59% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$12.1 million in 2021, then surged by 137.64% to $4.6 million in 2022, then tumbled by 45.71% to $2.5 million in 2023, then tumbled by 189.9% to -$2.2 million in 2024, then soared by 411.87% to $6.9 million in 2025.
• Per Business Quant, the three latest CRBP Net Cash Flow figures stand at $6.9 million (Q3 2025), $1.1 million (Q2 2025), and $1.7 million (Q1 2025).